1120 In vitro percutaneous absorption of extemporaneously compounded estradiol formulations

Extemporaneously compounded bioidentical hormones are commonly dispensed in the United States. However, questions have been raised regarding safety, effectiveness and use of hormone replacement therapy (cHRT). There is a need for clinical scientific evidence on cHRT, particular topically applied hormones. An vitro study was conducted to evaluate human skin percutaneous absorption estradiol, using Franz Skin Finite Dose Model. aqueous cream (VersaBase Cream) an anhydrous gel Anhydrous HRT) were prepared estradiol 0.06%, also 0.06% / estriol 0.1% (biest). The commercial medication ESTROGel (estradiol 0.06%) used as positive control. Estradiol concentrations analyzed ELISA. extemporaneously formulations exhibited similar rate absorption, characterized by steady mean flux that increased slightly up around 8 hours, decreased towards end (24 hours). ESTROGel, other hand, quick rise peak at approximately 1 hour after dose application, followed decline over time (up 4 hours), then well study. Upon 24 hours topical cumulative biest gel, cream, 1080.9±862.8 ng/cm2, 1073.6±668.8 752.8±405.9 737.2±313.6 ng/cm2 516.8±158.1 respectively. It demonstrated penetrates through upon application formulations. These results important support cHRT since model has proven accurately predict vivo permeation kinetics.